Biovail Files 2nd Suit To Protect Blood Pressure Drug

Law360, New York (October 19, 2005, 12:00 AM EDT) -- After filing a new suit earlier this week, Biovail Laboratories now has two patent infringement lawsuits pending against Andrx Pharmaceuticals in the same court over the same drug.

The new Biovail suit comes in response to an amended Abbreviated New Drug Application filed by Andrx for the drug blood pressure reducing drug Cardizem.

While the original ANDA only sought permission to produce 420 mg tablets of the drug, the amendment requests approval for 120, 180, 240, 300, and 360 mg. versions.

Biovail is seeking an injunction...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.